Lab study finds two routes to cancer-fueling inflammation

For nearly a month, Viviana I. Risca’s team watched cancer cells stop dividing, reorganize their DNA and change the signals they sent to their surroundings. The laboratory study, published in Life Science Alliance, found that two cancer therapies can lead to the same inflammatory program, which may encourage tumor growth, by taking different biological routes.

The cells entered senescence: a permanent growth arrest in which they no longer divide but also do not die. They continued releasing the SASP, a collection of signaling molecules that reshapes nearby tissue. The researchers studied cell models of liposarcoma and estrogen-receptor-positive breast cancer, using doxorubicin and palbociclib.

Doxorubicin damages DNA and activates NF-κB, a regulator of inflammatory genes, through the expected DNA-damage pathway. Palbociclib belongs to the CDK4/6 inhibitor class, which stops the cell cycle without directly damaging DNA. Yet its effects were not inert: the cells first produced tissue-remodeling signals, which gradually activated NF-κB through receptors on the cell surface.

The timing was central. Senescence did not appear as a single, fixed state. An early wave of tissue-remodeling signals was followed weeks later by delayed inflammation. Blocking DNA-damage sensors stopped inflammatory signaling after doxorubicin, but not after palbociclib. Blocking NF-κB itself suppressed the inflammatory response while preserving the cells’ growth arrest.

And so, concretely? The finding gives researchers a way to separate two consequences of therapy-induced senescence: stopping cancer-cell division and limiting the inflammation that may encourage tumor growth. It could inform future drug combinations, but the evidence here comes from laboratory cell models;